Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $632.00

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) had its price objective hoisted by stock analysts at Morgan Stanley from $605.00 to $632.00 in a report issued on Tuesday, MarketBeat reports. The firm currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective suggests a potential downside of 13.65% from the stock’s previous close.

Several other research firms have also issued reports on REGN. Barclays boosted their price target on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “overweight” rating in a report on Tuesday. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $694.00 price target for the company in a report on Monday, January 10th. Truist Financial cut their price target on Regeneron Pharmaceuticals from $754.00 to $728.00 and set a “buy” rating for the company in a report on Tuesday, February 8th. BMO Capital Markets reissued a “buy” rating and set a $780.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, February 11th. Finally, Bank of America lowered Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $675.00 to $575.00 in a research note on Wednesday, January 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $727.94.

Shares of REGN opened at $731.89 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.56 and a quick ratio of 3.07. Regeneron Pharmaceuticals has a one year low of $477.92 and a one year high of $747.42. The firm has a market capitalization of $78.71 billion, a P/E ratio of 10.15, a PEG ratio of 1.25 and a beta of 0.21. The business has a fifty day moving average of $656.07 and a 200 day moving average of $629.33.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last issued its quarterly earnings data on Friday, February 4th. The biopharmaceutical company reported $23.72 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $18.49 by $5.23. Regeneron Pharmaceuticals had a return on equity of 55.11% and a net margin of 50.24%. The company had revenue of $4.95 billion during the quarter, compared to analyst estimates of $4.49 billion. During the same quarter in the previous year, the company posted $8.72 earnings per share. Regeneron Pharmaceuticals’s revenue was up 104.4% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals will post 45.56 EPS for the current fiscal year.

In other news, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 1st. The stock was sold at an average price of $607.46, for a total transaction of $607,460.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Marc Tessier-Lavigne sold 7,439 shares of the business’s stock in a transaction that occurred on Monday, March 21st. The stock was sold at an average price of $690.00, for a total value of $5,132,910.00. The disclosure for this sale can be found here. Insiders have sold a total of 44,459 shares of company stock valued at $30,177,797 in the last quarter. Company insiders own 10.76% of the company’s stock.

A number of hedge funds have recently bought and sold shares of REGN. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in shares of Regeneron Pharmaceuticals by 0.7% in the 1st quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 10,913 shares of the biopharmaceutical company’s stock valued at $7,622,000 after acquiring an additional 71 shares during the last quarter. Traynor Capital Management Inc. grew its stake in Regeneron Pharmaceuticals by 3.9% during the 1st quarter. Traynor Capital Management Inc. now owns 17,944 shares of the biopharmaceutical company’s stock worth $12,532,000 after buying an additional 671 shares during the last quarter. Capital Investment Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $215,000. Shikiar Asset Management Inc. lifted its position in Regeneron Pharmaceuticals by 1.0% during the 1st quarter. Shikiar Asset Management Inc. now owns 3,619 shares of the biopharmaceutical company’s stock worth $2,528,000 after acquiring an additional 35 shares during the period. Finally, Capstone Wealth Management Group LLC lifted its position in Regeneron Pharmaceuticals by 2.6% during the 1st quarter. Capstone Wealth Management Group LLC now owns 855 shares of the biopharmaceutical company’s stock worth $597,000 after acquiring an additional 22 shares during the period. 82.97% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.